These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1254 related items for PubMed ID: 28446674
1. Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes. Filskov J, Mikkelsen M, Hansen PR, Christensen JP, Thomsen AR, Andersen P, Bukh J, Agger EM. J Virol; 2017 Jul 15; 91(14):. PubMed ID: 28446674 [Abstract] [Full Text] [Related]
2. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Jin B, Wang RY, Qiu Q, Sugauchi F, Grandinetti T, Alter HJ, Shih JW. Immunology; 2007 Sep 15; 122(1):15-27. PubMed ID: 17451465 [Abstract] [Full Text] [Related]
3. Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon-α, Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice. Kitagawa K, Omoto C, Oda T, Araki A, Saito H, Shigemura K, Katayama T, Hotta H, Shirakawa T. Viral Immunol; 2017 Apr 15; 30(3):196-203. PubMed ID: 28112593 [Abstract] [Full Text] [Related]
4. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV. Marín MQ, Pérez P, Ljungberg K, Sorzano CÓS, Gómez CE, Liljeström P, Esteban M, García-Arriaza J. J Virol; 2019 Apr 01; 93(7):. PubMed ID: 30674625 [Abstract] [Full Text] [Related]
5. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, Rosen HR. Hepatology; 2003 Mar 01; 37(3):577-89. PubMed ID: 12601356 [Abstract] [Full Text] [Related]
6. Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses. Zhang S, Bakshi RK, Suneetha PV, Fytili P, Antunes DA, Vieira GF, Jacobs R, Klade CS, Manns MP, Kraft AR, Wedemeyer H, Schlaphoff V, Cornberg M. J Virol; 2015 Aug 01; 89(16):8304-17. PubMed ID: 26041301 [Abstract] [Full Text] [Related]
7. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, Christensen JP. J Immunol; 2011 Feb 15; 186(4):2355-64. PubMed ID: 21257961 [Abstract] [Full Text] [Related]
9. [The combined application of nucleotide and amino acid sequences of NS3 hepatitis C virus protein, DNA encoding granulocyte macrophage colony-stimulating factor and inhibitor of regulatory T cells induces effective immune response against hepatitis C virus]. Masalova OV, Lesnova EI, Shingarova LN, Tunitskaia VL, Ulanova TI, Burkov AN, Kushch AA. Mol Biol (Mosk); 2012 Feb 15; 46(3):525-34. PubMed ID: 22888642 [Abstract] [Full Text] [Related]
10. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice. Guan J, Deng Y, Chen H, Yin X, Yang Y, Tan W. Arch Virol; 2015 Oct 15; 160(10):2517-24. PubMed ID: 26215441 [Abstract] [Full Text] [Related]
11. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs. Sugauchi F, Wang RY, Qiu Q, Jin B, Alter HJ, Shih JW. J Infect Dis; 2006 Feb 15; 193(4):563-72. PubMed ID: 16425136 [Abstract] [Full Text] [Related]
15. An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines. Koutsoumpli G, Stasiukonyte N, Hoogeboom BN, Daemen T. Vaccine; 2024 Sep 17; 42(22):126032. PubMed ID: 38964950 [Abstract] [Full Text] [Related]
16. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Zeng R, Li G, Ling S, Zhang H, Yao Z, Xiu B, He F, Huang R, Wei L. Antiviral Res; 2009 Oct 17; 84(1):23-30. PubMed ID: 19646486 [Abstract] [Full Text] [Related]
17. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Fytili P, Dalekos GN, Schlaphoff V, Suneetha PV, Sarrazin C, Zauner W, Zachou K, Berg T, Manns MP, Klade CS, Cornberg M, Wedemeyer H. Vaccine; 2008 Jul 23; 26(31):3818-26. PubMed ID: 18582999 [Abstract] [Full Text] [Related]
18. Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein. Martin P, Parroche P, Pajot A, Chatel L, Barreto C, Touat L, Dubois V, Rohrlich PS, Bain C, Trépo C, Negro F, Inchauspé G, Fournillier A. Microbes Infect; 2006 Aug 23; 8(9-10):2432-41. PubMed ID: 16859951 [Abstract] [Full Text] [Related]
19. Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination. Gupte GM, Arankalle VA. Virol J; 2012 Mar 27; 9():74. PubMed ID: 22452828 [Abstract] [Full Text] [Related]